GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...
Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...
The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.
Age differences are seen in the efficacy of treatments for type 2 diabetes, according to study results published in the Journal of the AMA.
The Janus Henderson Global Sustainable Equity Managed Account Portfolio returned -5.71% (gross) for Q4 2024. Click here to ...
Health experts say popular weight-loss drugs like Ozempic and Wegovy are safe, but the FDA warns counterfeits are becoming more widespread.
Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body shapes and sizes.
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
Axplora, a German CDMO that specializes in API small molecule and ADC production, will upgrade its manufacturing facility in ...
A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.